CHBIO (6534) reported revenue of NT$62 million for Oct 2026, -26.4% year on year and -47.6% from the previous month. Revenue for Jan–Oct 2026 was NT$1.61 billion (+2.3% year on year).
In Oct 2026, it ranked No. 93 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$62 million | -26.4% | -47.6% |
| Sep 2026 | NT$118.3 million | +11.5% | +196.5% |
| Aug 2026 | NT$39.9 million | -33.4% | -35.9% |
| Jul 2026 | NT$62.2 million | +22.7% | -30.0% |
| Jun 2026 | NT$88.9 million | +28.6% | -37.1% |
| May 2026 | NT$141.4 million | +7.3% | -38.3% |
| Apr 2026 | NT$229.2 million | +4.4% | -39.3% |
| Mar 2026 | NT$377.3 million | +2.5% | +38.3% |
| Feb 2026 | NT$272.9 million | +2.1% | +24.4% |
| Jan 2026 | NT$219.3 million | +0.6% | +43.3% |
| Dec 2025 | NT$153 million | +13.7% | +67.8% |
| Nov 2025 | NT$91.2 million | +32.4% | +8.3% |
| Oct 2025 | NT$84.2 million | +17.0% | -20.6% |
| Sep 2025 | NT$106.1 million | +94.7% | +77.1% |
| Aug 2025 | NT$59.9 million | +84.4% | +18.1% |
| Jul 2025 | NT$50.7 million | +6.0% | -26.6% |
| Jun 2025 | NT$69.1 million | +2.9% | -47.6% |
| May 2025 | NT$131.8 million | +3.2% | -40.0% |
| Apr 2025 | NT$219.6 million | +6.7% | -40.4% |
| Mar 2025 | NT$368.3 million | +4.4% | +37.8% |
| Feb 2025 | NT$267.3 million | +6.9% | +22.6% |
| Jan 2025 | NT$218.1 million | -1.8% | +62.1% |
| Dec 2024 | NT$134.6 million | +83.0% | +95.4% |
| Nov 2024 | NT$68.9 million | +31.1% | -4.3% |
| Oct 2024 | NT$72 million | +307.6% | +32.1% |
Jan–Oct 2026 cumulative: NT$1.61 billion (+2.3% YoY)
Other Biotech & Medical companies
Compare with peers: CHBIO vs PEC / CHBIO vs Lotus Pharm / CHBIO vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16